let ntp = {
    "inv3": "Inv(3) or t(3;3) can be seen in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In AML, inv(3) or t(3;3) constitutes a distinct genetic subtype that is associated with normal or elevated platelet counts, increased dysplastic megakaryocytes with unilobed or bilobed nuclei, multilineage dysplasia, and a poor prognosis. This cytogenetic abnormality is also associated with a poor prognosis in myelodysplastic syndrome (MDS).  It is associated with deregulated GATA2 and MECOM expression. ",

    "chr5": "Deletion of the long arm of chromosome 5 is a recurring abnormality in myeloid disorders (MDS and AML).  Myelodysplastic syndrome (MDS) with isolated del(5q), also known as 5q- syndrome, is defined by deletion of 5q occurring either in isolation or with one other cytogenetic abnormality other than monosomy 7 or deletion of 7q, and without excess blasts. This MDS subtype is typically associated with response to lenalidomide and a good prognosis.  However, the concurrent presence of a TP53 mutation predicts a poorer response to lenalidomide and higher risk of transformation to acute myeloid leukemia (AML).  If clinically indicated, TP53 mutation analysis may be considered for further evaluation.  In AML, deletion of 5q is an adverse prognostic sign. <br><br> Please correlate with other clinical and laboratory information.",

    "mono5": "Monosomy 5 is a recurring cytogenetic abnormality in myeloid neoplasms, especially myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In MDS, deletion of 5q occurring either in isolation or with one other cytogenetic abnormality other than monosomy 7 or deletion of 7q is associated with a favorable prognosis. In contrast, monosomy 5 is usually seen as part of a complex karyotype, and in that context is associated with a poor prognosis.  In AML, monosomy 5 is assigned a poor prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "del5q7q": "Loss of 5q and 7q excludes a diagnosis of MDS with isolated 5q deletion in the WHO classification.  This combination is assigned a poor prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS.  In AML, this combination is an adverse prognostic sign.  ",

    "tr69": "In the current WHO classification, the t(6;9) translocation is presumptive evidence for myelodysplasia in the setting of persistent cytopenia of undetermined origin but without morphologic evidence of myelodysplasia and is also a recurrent anomaly in AML.  In the setting of AML, is does not qualify, however, as sufficient for diagnosis of AML with myelodysplasia-related changes.  In acute myeloid leukemia (AML), the t(6;9) resulting in DEK-NUP214 fusion is assigned a poor prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification. ",

    "chr7": "Deletion of the long arm of chromosome 7 is a recurring abnormality in myeloid disorders (MDS and AML). In myelodysplastic syndrome (MDS), as the sole cytogenetic abnormality, it is assigned an intermediate prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS but a poor prognosis when present with an additional anomaly.",

    "mono7": "Monosomy 7 is a recurring abnormality in myeloid neoplasms. In myelodysplastic syndrome (MDS) and in acute myeloid leukemia (AML) it is associated with a poor prognosis according to the Revised International Prognostic Scoring System (IPSS-R) and European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "chr8": "In myelodysplastic syndrome (MDS), trisomy 8 as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS. In the setting of persistent cytopenia of undetermined origin, however, trisomy 8 as a sole cytogenetic abnormality in the absence of morphologic criteria is not considered definitive of MDS. In acute myeloid leukemia (AML), trisomy 8 as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification. ",

    "chr11": "In acute myeloid leukemia (AML), KMT2A (MLL) rearrangements are assigned a poor prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification, except for the t(9;11)(p21.3;q23.3) involving KMT2A-MLLT3, which is assigned an intermediate prognosis. ",

    "chr11del": "In myelodysplastic syndrome (MDS), deletion of 11q as a sole cytogenetic abnormality is assigned a very good prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS.  However, in acute myeloid leukemia (AML), deletion of 11q as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification. ",

    "chr11delPartial": "This signal pattern may be the result of an isolated partial deletion of the KMT2A gene or deletion associated with an unbalanced translocation resulting from retention of the derivative chromosome 11 with the 5’ region of the gene and loss of the reciprocal derivative chromosome with the 3’ region of the gene. The clinical significance of the findings is unclear as deletion of 11q as a sole cytogenetic abnormality is assigned a very good prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS, but KMT2A (MLL) gene rearrangements are generally associated with an unfavorable prognosis in myeloid neoplasms except for the t(9;11) translocation, involving KMT2A-MLLT3, which is assigned an intermediate prognosis in the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "chr11gain": "Gain of KMT2A signal without rearrangement may occur through a duplication of the locus or gain of chromosome 11/11q.  Gain of the long arm of chromosome 11, including band q23, is a recurring abnormality in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). While trisomy 11 as a sole cytogenetic abnormality is assigned an intermediate prognosis in MDS and AML according to the Revised International Prognostic Scoring System (IPSS-R) and European LeukemiaNet (ELN), respectively, some studies have shown trisomy 11 to be associated a poor prognosis. ",

    "chr11amp": "KMT2A gene amplification can be present as internal partial tandem duplication (PTD) at the molecular level and/or as homogenously staining region (hsr) and double minutes (dmin) detectable by cytogenetic analysis. It may be seen in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and mixed-phenotype acute leukemia (MPAL) and is associated with poor prognosis.",

    "chr11rearr":"In acute myeloid leukemia (AML), KMT2A (MLL) rearrangements are assigned a poor prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification, except for the t(9;11)(p21.3;q23.3) involving KMT2A-MLLT3, which is assigned an intermediate prognosis. ",

    "ETV6del": "In myelodysplastic syndrome (MDS), deletion of 12p as a sole cytogenetic abnormality is assigned a good prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS. In acute myeloid leukemia (AML), deletion of 12p as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "ETV6rearr": "ETV6 rearrangements rarely observed in myeloid neoplasms. When detected they are associated with the presence of other genetic abnormalities. In de novo acute myeloid leukemia (AML), ETV6 rearrangement appears to be associated with an intermediate prognosis. ",

    "inv16": "In acute myeloid leukemia (AML), the inv(16) or t(16;16) resulting in CBFB-MYH11 fusion is assigned a favorable prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification and is diagnostic of AML regardless of blast count in the current WHO classification. KIT mutations occur in approximately 30% of cases and are associated with less favorable prognosis and a higher risk of relapse. FLT3 mutations and trisomy 8 are also associated with worse outcome.",

    "del16q": "In acute myeloid leukemia (AML), deletion of 16q as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.  It is not associated with CBFB rearrangement.",

    "TP53": "In myelodysplastic syndrome (MDS), deletion of 17p is commonly seen as part of a complex karyotype. As complex karyotypes are associated with poor prognosis, studies including chromosome analysis to investigate for a complex karyotype is recommended, if not already performed. In acute myeloid leukemia (AML), loss of material from the short arm of chromosome 17 is assigned a poor prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "mono17": "In myelodysplastic syndrome (MDS), monosomy 17 is commonly seen as part of a complex karyotype. As complex karyotypes are associated with poor prognosis, studies including chromosome analysis to investigate for a complex karyotype is recommended, if not already performed.",

    "iso17q": "In myelodysplastic syndrome (MDS), isochromosome 17q as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS. ",

    "tri19": "In myelodysplastic syndrome (MDS), trisomy 19 as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS. ",

    "tet19": "Trisomy/tetrasomy 19 is strongly associated with myeloid disorders and is an in the IPSS-R Cytogenetic Scoring system is an intermediate-risk prognostic sign. ",

    "chr20": "In myelodysplastic syndrome (MDS), deletion of 20q as a sole cytogenetic abnormality is assigned a good prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS. In the setting of persistent cytopenia of undetermined origin, however, deletion of 20q as a sole cytogenetic abnormality in the absence of morphologic criteria is not considered definitive of MDS. In acute myeloid leukemia (AML), loss of material from the long arm of chromosome 20 as a sole cytogenetic abnormality is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "complex": "The presence of a complex karyotype (3 or more abnormalities) is associated with a poor prognosis in MDS and AML.  ",

    "complexGT3": "In myelodysplastic syndrome (MDS), complex karyotype with >3 cytogenetic abnormalities is assigned a very poor prognosis according to the Revised International Prognostic Scoring System (IPSS-R) for MDS.",

    "congruent": "These results are congruent with the most recent cytogenetic analysis on file (CYG22-",

    "correlate": "Please correlate with other clinical and laboratory information, including the pending cytogenetic analysis (CYG23-",

    "whomds": "In the current WHO guidelines, the demonstration of MDS-defining anomalies in a cytopenic patient in the absence of morphologic dysplasia must be by conventional karyotyping to be diagnostic. ",

    "RUNX1": "The demonstration of t(8;21)/RUNX1-RUNX1T1 fusion is diagnostic of AML regardless of blast count in the current WHO classification.  This fusion is assigned a favorable prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification. However, some studies have shown the concurrent presence of KIT mutation to be associated with decreased remission duration and overall survival. If clinically indicated, KIT mutation analysis may be considered for further evaluation. ",

    "RUNX1T1gain": "Gain of signal with the RUNX1T1 probe  may be indicative of trisomy 8, which is assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.  However, the possibility that it is the result of a RUNX1T1 rearrangement with a gene other than RUNX1 cannot be ruled out.",

    "RUNX1gain": "Gain of RUNX1 signal is suggestive of RUNX1 rearrangement with a gene other than RUNX1T1 or trisomy 21. RUNX1 rearrangement to partner genes other than RUNX1T1 as well as trisomy 21 are both assigned an intermediate prognosis according to the European LeukemiaNet (ELN) recommendations for AML risk stratification.",

    "RARA": "The demonstration of t(15;17)/PML-RARA fusion is diagnostic of acute promyelocytic leukemia (FAB-M3) regardless of blast count in the current WHO classification and is associated with response to all-trans retinoic acid (ATRA) and /or arsenic trioxide (ATO). ",

    "RARA3G":  "The additonal RARA signal in the PML/RARA probe set (2R3G) may be associated with gain of chromosome 17q, including through formation of an isochromsome 17q, or RARA rearrangement with a locus other than PML.  If clinically indicated, further evaluation for rearrangement of this locus with the RARA breakapart probe set should be considered.",

    "RARAbreak": "RARA gene rearrangement is identified with the RARA breakapart probe. The clinical significance of the rearrangement is dependent on the partner gene involved in the rearrangement. This assay is not designed to detect the fusion partner.  Cytogenetic studies may aid in further characterization of the RARA abnormality.",

    "allothers": "All other probe signals were within normal reference ranges. These findings represent an ABNORMAL result.",

    "multipleGains": "Multiple chromosome gains are usually associated with complex karyotypes, which carry an unfavorable prognosis in AML, although simple gains do not.  For complete interpretation, please correlate with other clinical and laboratory information including the pending cytogenetic analysis (CYG22- .",

    "noTargeted": "No targeted rearrangements are identified.",

}
//line breaks have to be given by '<br/>' and without any carriage returns; else error; JSON.parse(JSON.stringify) not required
let references = {
    "inv3": ["Swerdlow", "Dohner", "Greenberg"],
    /* Swerdlow S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Rev. 4th ed. Lyon, France: IARC;2017 <br>  Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.<br/>Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.", */

    "mono5": ["Swerdlow", "Greenberg"],     /* Swerdlow S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Rev. 4th ed. Lyon, France: IARC;2017.<br/> Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.", */

    "chr5": ["Greenberg", "Schanz", "Swerdlow", "Jadersten"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. <br/> Swerdlow S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Rev. 4th ed. Lyon, France: IARC;2017.<br/> Jadersten M, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971-9. ", */

    "del5q7q": ["Swerdlow", "Schanz", "Greenberg"],

    "tr69": ["Swerdlow", "Dohner"],

    "mono7": ["Swerdlow", "Greenberg"],     /* Swerdlow S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Rev. 4th ed. Lyon, France: IARC;2017.<br/> Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120(12):2454-65. ", */

    "chr7": ["Greenberg", "Schanz"],    /*  Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ",
 */
    "chr8": ["Greenberg", "Schanz", "Swerdlow"],  /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.<br/> Swerdlow S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Rev. 4th ed. Lyon, France: IARC;2017.",
 */
    "chr20": ["Greenberg", "Schanz", "Swerdlow"],  /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.<br/> Swerdlow S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Rev. 4th ed. Lyon, France: IARC;2017.", */


    "chr11": ["Swerdlow", "Dohner"],    /*  Swerdlow S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Rev. 4th ed. Lyon, France: IARC;2017.<br/> Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447", */

    "chr11del": ["Greenberg", "Schanz","Swerdlow", "Dohner"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ", */

    "chr11delPartial": ["Greenberg", "Schanz", "Dohner", "Swerdlow"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.<br/> Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. ", */

    "chr11gain": ["Greenberg", "Dohner", "Wang", "Alseraye"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;20;120(12):2454-65.<br/> Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.<br/> Wang SA, et al. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia. 2010;24(4):740-7. <br/> Alseraye FM, et al. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation. Int J Clin Exp Pathol. 2011;4(4):371-7.", */

    "chr11amp": ["Sak"],

    "chr11rearr": ["Swerdlow", "Dohner"],

    "ETV6del": ["Greenberg", "Schanz", "Swerdlow", "Dohner"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ",
 */
    "ETV6rearr": ["Dohner", "Haferlach"],     /* Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. <br/> Haferlach C, et al. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012;51(4):328-37.", */

    "inv16": ["Swerdlow", "Dohner"],

    "del16q": ["Swerdlow", "Dohner"],

    "mono17": ["Greenberg", "Schanz"],    /*  Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/>  Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ", */

    "TP53": ["Greenberg", "Schanz", "Swerdlow", "Dohner"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9. ", */

    "iso17q": ["Greenberg", "Schanz"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.", */

    "tri19": ["Greenberg", "Schanz"],     /* Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br/> Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9." */

    "RARA": ["Swerdlow", "Dohner"],

    "RARAbreak": ["Swerdlow"],

    "RUNX1": ["Swerdlow", "Dohner"],

    "RUNX1gain": ["Swerdlow", "Dohner"],

    "RUNX1T1gain": ["Swerdlow", "Dohner"],

    "multipleGains": ["Chilton"],
    "RARA3G": "",
    "noTargeted":"",
    "complex": ["Schanz", "Greenberg", "Dohner"],
}
let reference_list = {
    "Swerdlow": "Swerdlow S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Rev. 4th ed. Lyon, France: IARC;2017<br>",

    "Dohner": "Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.<br>",

    "Greenberg": "Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.<br>",

    "Schanz": "Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.<br>",

    "Jadersten": "Jadersten M, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971-9.<br> ",

    "Dohner": "Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.<br>",

    "Wang": "Wang SA, et al. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia. 2010;24(4):740-7.<br>",

    "Alseraye": "Alseraye FM, et al. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation. Int J Clin Exp Pathol. 2011;4(4):371-7.<br>",

    "Haferlach": "Haferlach C, et al. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012;51(4):328-37.<br>",

    "Sak": "Sakhdari A et al.  Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).  Ca Genet. 2019;238:18-22.<br>",

    "Chilton":"Chilton L et al.  Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome.  Leukemia 2014;28:321-328.<br>",
   
}


let reference_array = [];//to hold all reference keys
let ref_unique_array = [];//only unique reference keys

function detectedAbnormality(ntpKey,reference){
$('<span>' + ntpKey + '<br>' + '<br>' +'</span>').appendTo('#allntp');
//write the same reference only once
for (let el of reference){reference_array.push(el);}
ref_unique_array = [...new Set(reference_array)];
let final_list=[];//to hold all unique reference values; local variable required else list will grow with each write
for (let el of ref_unique_array){final_list.push(reference_list[el])}
final_list_string = final_list.toString().replace(/<br>,/g , "<br>");  //regex to stop printing of comma before references
document.querySelector("#references").innerHTML=final_list_string;
}

function atypicalPattern(ntpKey){
    $('<span>' + ntpKey + '&nbsp' +'</span>').appendTo('#test');
    $('<span>' + "ATYPICAL INTERPRETATION HERE" + '<br>' + '<br>' + '</span>').appendTo('#allntp');
}
function copyToClipboard() {
  var copyText =
    document.getElementById("reportText").innerText +
    document.getElementById("allReferences").innerText
  navigator.clipboard.writeText(copyText);
  console.log(copyText);
}

function copyInterpToClipboard(){
    var copyText = document.querySelector("#allntp").innerText;
    navigator.clipboard.writeText(copyText);
}

function copyRefsToClipboard(){
    var copyText = document.querySelector("#references").innerText;
    navigator.clipboard.writeText(copyText);
}

function viewItem(div) {
    var x = document.getElementById(div);
    if (x.style.display === "none") {
      x.style.display = "block";
    } else {
      x.style.display = "none";
    }
}
